Lupin gets USFDA’s nod for Generic Albuterol Sulphate MDI

25 Aug 2020 Evaluate

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation, a generic version of ProAir HFA. The company’s generic Albuterol Sulphate MDI will be manufactured at its Indore (Unit III) facility in India.

ProAir HFA (Albuterol Sulfate Inhalation Aerosol) is the registered trademark of Teva Branded Pharmaceutical Products R&D, Inc. (Teva) and is indicated for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms. The total Albuterol Sulfate Inhalation Aerosol market had U.S. sales of approximately $2.9 billion, of which the ProAir HFA market accounted for $1.3 billion (IQVIA MAT June 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2073.20 18.15 (0.88%)
11-Dec-2025 11:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.00
Dr. Reddys Lab 1268.20
Cipla 1501.55
Zydus Lifesciences 922.85
Lupin 2073.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×